Loading clinical trials...
Loading clinical trials...
A Phase III, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Chinese Patients in Chronic Phase
Conditions
Interventions
Radotinib
Imatinib
Locations
1
China
Peking University People's Hospital(北京大学人民医院)
Beijing, China
Start Date
December 28, 2018
Primary Completion Date
March 3, 2023
Completion Date
June 30, 2025
Last Updated
October 28, 2024
NCT05143840
NCT06119269
NCT03459534
NCT06233890
NCT04126681
NCT06516029
Lead Sponsor
Il-Yang Pharm. Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions